Effect of TMS on Neuropathic Pain for Patients With Sci

NCT07293780 | Recruiting

• 1 other identifier: AEŞH-EK-2025-102
• Study Type: interventional
• Target: 39
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of this study is to evaluate the efficacy of rTMS targeting the anterior cingulate cortex, another stimulation site that may be effective in the treatment of neuropathic pain, and to compare it with motor cortex stimulation.

Conditions

Spinal Cord Injury; Neuropathic Pain

Outcome Measures

Primary Outcomes (1)

• visual analog scale

  The assessment of pain using a 10 cm visual analogue scale (VAS), separately for daytime and night-time. The assessment will be conducted on a scale of "0 = no pain" to "10 = the most severe pain imaginable".

  first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

Secondary Outcomes (3)

• neuropathic pain scale

  first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

• Beck Depression Scale

  first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

• 5-point Likert scale

  first day of treatment, at the end of treatment (at 2nd week), 4 week after end of treatment, 12 week after end of treatment

Study Arms (3)

active rTMS primer motor cortex

ACTIVE COMPARATOR

Device: active TMS

rTMS anterior cingulate gyrus

EXPERIMENTAL

Device: active TMS

sham rTMS primer motor cortex

SHAM COMPARATOR

Device: sham TMS

Interventions

active TMS DEVICE

Patients in the active or sham primary motor cortex rTMS group will receive active or sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks. Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision.

active rTMS primer motor cortex; rTMS anterior cingulate gyrus

sham TMS DEVICE

Patients in the active or sham primary motor cortex rTMS group will receive active or sham rTMS at 5 Hz targeting the M1 area of the lower extremity motor area under medical supervision for a total of 10 sessions over 2 weeks. Patients in the active anterior cingulate cortex rTMS group will also receive active 5 Hz rTMS targeting the anterior cingulate cortex for a total of 10 sessions over 2 weeks under medical supervision.

sham rTMS primer motor cortex

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients for whom at least 12 months have passed since the date of the event
• Patients who meet the International Pain Working Group's criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months
• Patients aged 18-65
• Pain not attributable to other causes such as rheumatological diseases or diabetes
• Patients with VAS \> 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, narcotics), exercise and physical therapy agents, taking into account renal function tests and other comorbidities

You may not qualify if:

• History of epilepsy
• Metallic implant in the scalp
• Cochlear implant
• Spinal cord stimulator
• Pacemaker
• Presence of psychiatric illness
• Pregnancy

Sponsors & Collaborators

• Ankara Etlik City Hospital: lead

Study Sites (2)

Ankara Etlik City Hospital

Ankara, Yenimahalle, 06010, Turkey (Türkiye)

RECRUITING

Gaziler Physical Therapy and Rehabilitation Training and Research Hospital

Ankara, Çankaya, 06800, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Spinal Cord Injuries; Neuralgia

Condition Hierarchy (Ancestors)

Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Trauma, Nervous System; Wounds and Injuries; Peripheral Nervous System Diseases; Neuromuscular Diseases; Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Ayşe Naz Kalem Özgen, specialist

CONTACT

+90 0312 797 00 00; kalemnaz@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: PM&R Specialist

Study Record Dates

• First Submitted: November 13, 2025
• First Posted: December 19, 2025
• Study Start: December 15, 2025
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): November 1, 2026
• Last Updated: February 24, 2026

Record last verified: 2026-02

Locations

TU (2)